Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

INmune Bio Updates Clinical Development and Commercialization Strategy | WAPE

FilingSEC EDGAR424B5

INmune Bio Updates Clinical Development and Commercialization Strategy

Oct 29, 2026, 07:30 ET · SEC accepted

StageLate-stage

Filing content

INmune Bio is preparing for MAA submission for Ebstrocel in the UK and announced a new financing round.

AI summary of the filing. Please also check the source.

Related companies

Inmune Bio, Inc.INMBView stock

Analyzed by WAPE AI.

Preparing English content…

Comments —

Comment

Loading comments…